Home/Pipeline/LYT-100 (deupirfenidone)

LYT-100 (deupirfenidone)

Fibrotic diseases (e.g., IPF)

Phase 2Active

Key Facts

Indication
Fibrotic diseases (e.g., IPF)
Phase
Phase 2
Status
Active
Companies

About PureTech Health

PureTech Health is a Boston-based biotech studio that creates and funds separate companies around innovative scientific discoveries, de-risking development and capturing value through equity and royalties. Its model has proven exceptionally successful, boasting a 6x higher clinical success rate than the industry average and delivering three FDA-approved therapies. The company's strategy leverages a deep network of academic collaborators and seasoned leadership to build a diversified portfolio across immunology, neurology, and gastroenterology.

View full company profile

About LianBio

LianBio's mission was to accelerate the availability of innovative medicines for patients in China and broader Asian markets by in-licensing clinical-stage assets from global partners. The company built an integrated regional development and commercialization platform to navigate complex regulatory and commercial landscapes. Its primary achievement was advancing a portfolio of promising candidates, including mavacamten for oHCM which reached NDA acceptance in China, before the Board's decision to wind down operations and liquidate the pipeline following a strategic review in November 2023.

View full company profile